Clinical trial NCT06653205: Prediction of Acute Pancreatitis Outcome
Official title: Systemic Inflammation Response Index and Systemic Immune Inflammation Index and Prediction of Clinical Outcome in Acute Pancreatitis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Acute
Pancreatitis
Keywords: Acute pancreatitis
Outcome
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-10-22
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient complaint of abdominal pain ,more than 18 years old,not known to have liver ,renal or malignant disease, typical abdominal ultrasound and computed tomography with findings of acute pancreatitis

Brief summary: Aim of study prediction of acute pancreatitis outcome by using cheap and available laboratory resources

Detailed description: Acute pancreatitis (AP) is a sudden inflammation of the pancreas that can vary from mild, self-resolving episodes to severe, potentially fatal conditions(1). Clinically, AP is classified into mild acute pancreatitis and severe acute pancreatitis (SAP), and SAP patients are described by multi-organ failure and high mortality rates(2). The mortality rate of acute pancreatitis varies, ranging from 3% in cases of mild edematous pancreatitis to as high as 20% in patients with pancreatic necrosis(3).The progression of AP can lead to systemic complications, making early prediction of clinical outcomes essential for effective management(4).

In recent years, there has been growing interest in identifying reliable biomarkers that can predict the severity and outcomes of acute pancreatitis(5). Systemic inflammation is a key factor in the pathophysiology of acute pancreatitis, often leading to systemic inflammatory response syndrome (SIRS) and subsequent organ dysfunction(6). Consequently, assessing systemic inflammation has become a crucial aspect of managing AP patients(7).

The Systemic Inflammation Response Index (SIRI) is recognized in the literature as an inflammatory marker that combines routine blood parameters, such as neutrophils, monocytes, and lymphocytes(8). Both SIRI and the Systemic Immune Inflammation Index (SII) are emerging as novel biomarkers for systemic inflammation(9). SIRI is calculated using neutrophil, monocyte, and lymphocyte counts, while SII is based on platelet, neutrophil, and lymphocyte counts(10)

Eligibility criteria: Inclusion Criteria:

Patients age \>18 years old Serum amylase \>3 times the upper limit of normal. abdominal pain consistent with acute pancreatitis. Typical abdominal ultrasonography and tomography findings in the routine imaging of the patients were accepted as acute pancreatitis.

Patient complaint of abdominal pain -

Exclusion Criteria:

liver diseases patients renal diseases patients malignancy patients

-

Primary outcomes:
measure: Mortality and severity of acute pancreatitis
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Biyik M, Biyik Z, Asil M, Keskin M. Systemic Inflammation Response Index and Systemic Immune Inflammation Index Are Associated with Clinical Outcomes in Patients with Acute Pancreatitis? J Invest Surg. 2022 Aug;35(8):1613-1620. doi: 10.1080/08941939.2022.2084187. Epub 2022 Jun 5.